Novel Platinum(II) compounds modulate insulin-degrading enzyme activity and induce cell death in neuroblastoma cells

Verfasser / Beitragende:
[Grazia Tundo, Diego Sbardella, Sandra De Pascali, Chiara Ciaccio, Massimo Coletta, Francesco Fanizzi, Stefano Marini]
Ort, Verlag, Jahr:
2015
Enthalten in:
JBIC Journal of Biological Inorganic Chemistry, 20/1(2015-01-01), 101-108
Format:
Artikel (online)
ID: 605506957
LEADER caa a22 4500
001 605506957
003 CHVBK
005 20210128100629.0
007 cr unu---uuuuu
008 210128e20150101xx s 000 0 eng
024 7 0 |a 10.1007/s00775-014-1217-3  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s00775-014-1217-3 
245 0 0 |a Novel Platinum(II) compounds modulate insulin-degrading enzyme activity and induce cell death in neuroblastoma cells  |h [Elektronische Daten]  |c [Grazia Tundo, Diego Sbardella, Sandra De Pascali, Chiara Ciaccio, Massimo Coletta, Francesco Fanizzi, Stefano Marini] 
520 3 |a The properties of three novel Platinum(II) compounds toward the insulin-degrading enzyme (IDE) enzymatic activity have been investigated under physiological conditions. The rationale of this study resides on previous observations that these compounds, specifically designed and synthesized by some of us, induce apoptosis in various cancer cell lines, whereas IDE has been proposed as a putative oncogene involved in neuroblastoma onset and progression. Two of these compounds, namely [PtCl(O,O′-acac)(DMSO)] and [Pt(O,O′-acac)(γ-acac)(DMS)], display a modulatory behavior, wherefore activation or inhibition of IDE activity occurs over different concentration ranges (suggesting the existence of two binding sites on the enzyme). On the other hand, [Pt(O,O′-acac)(γ-acac)(DMSO)] shows a typical competitive inhibitory pattern, characterized by a meaningful affinity constant (K i =0.95±0.21μM). Although all three compounds induce cell death in neuroblastoma SHSY5Y cells at concentrations exceeding 2μM, the two modulators facilitate cells' proliferation at concentrations≤1.5μM, whereas the competitive inhibitor [Pt(O,O′-acac)(γ-acac)(DMSO)] only shows a pro-apoptotic activity at all investigated concentrations. These features render the [Pt(O,O′-acac)(γ-acac)(DMSO)] a promising "lead compound” for the synthesis of IDE-specific inhibitors (not characterized yet) with therapeutic potentiality. 
540 |a SBIC, 2014 
690 7 |a Insulin-degrading enzyme  |2 nationallicence 
690 7 |a Cisplatin  |2 nationallicence 
690 7 |a Neuroblastoma  |2 nationallicence 
690 7 |a Platinum(II) compounds  |2 nationallicence 
700 1 |a Tundo  |D Grazia  |u Department of Clinical Sciences and Translational Medicine, University of Roma Tor Vergata, Via Montpellier 1, 00133, Rome, Italy  |4 aut 
700 1 |a Sbardella  |D Diego  |u Department of Clinical Sciences and Translational Medicine, University of Roma Tor Vergata, Via Montpellier 1, 00133, Rome, Italy  |4 aut 
700 1 |a De Pascali  |D Sandra  |u CIRCMSB, Via C. Ulpiani 27, 70125, Bari, Italy  |4 aut 
700 1 |a Ciaccio  |D Chiara  |u Department of Clinical Sciences and Translational Medicine, University of Roma Tor Vergata, Via Montpellier 1, 00133, Rome, Italy  |4 aut 
700 1 |a Coletta  |D Massimo  |u Department of Clinical Sciences and Translational Medicine, University of Roma Tor Vergata, Via Montpellier 1, 00133, Rome, Italy  |4 aut 
700 1 |a Fanizzi  |D Francesco  |u CIRCMSB, Via C. Ulpiani 27, 70125, Bari, Italy  |4 aut 
700 1 |a Marini  |D Stefano  |u Department of Clinical Sciences and Translational Medicine, University of Roma Tor Vergata, Via Montpellier 1, 00133, Rome, Italy  |4 aut 
773 0 |t JBIC Journal of Biological Inorganic Chemistry  |d Springer Berlin Heidelberg  |g 20/1(2015-01-01), 101-108  |x 0949-8257  |q 20:1<101  |1 2015  |2 20  |o 775 
856 4 0 |u https://doi.org/10.1007/s00775-014-1217-3  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s00775-014-1217-3  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Tundo  |D Grazia  |u Department of Clinical Sciences and Translational Medicine, University of Roma Tor Vergata, Via Montpellier 1, 00133, Rome, Italy  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Sbardella  |D Diego  |u Department of Clinical Sciences and Translational Medicine, University of Roma Tor Vergata, Via Montpellier 1, 00133, Rome, Italy  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a De Pascali  |D Sandra  |u CIRCMSB, Via C. Ulpiani 27, 70125, Bari, Italy  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Ciaccio  |D Chiara  |u Department of Clinical Sciences and Translational Medicine, University of Roma Tor Vergata, Via Montpellier 1, 00133, Rome, Italy  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Coletta  |D Massimo  |u Department of Clinical Sciences and Translational Medicine, University of Roma Tor Vergata, Via Montpellier 1, 00133, Rome, Italy  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Fanizzi  |D Francesco  |u CIRCMSB, Via C. Ulpiani 27, 70125, Bari, Italy  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Marini  |D Stefano  |u Department of Clinical Sciences and Translational Medicine, University of Roma Tor Vergata, Via Montpellier 1, 00133, Rome, Italy  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t JBIC Journal of Biological Inorganic Chemistry  |d Springer Berlin Heidelberg  |g 20/1(2015-01-01), 101-108  |x 0949-8257  |q 20:1<101  |1 2015  |2 20  |o 775